GlaxoSmithKline employs ‘new way of thinking’ by using 23andMe’s genetic data to launch cancer drug trial

GlaxoSmithKline and 23andMe are currently dealing with nearly 30 programs intended at developing new immunology, oncology neurology, cardiovascular and metabolic drugs. Many of these projects are still in their infancy phases.

In 2018, GlaxoSmithKline purchased a $300 million stake in 23andMe to use the Sunnyvale, Calif.-based businesss DNA database to develop new treatments by better understanding how genes affect illness.

More articles on pharmacy: Trumps conference with pharma execs canceled after drug lobbies decline to reveal upHy-Vee to roll out curbside flu shot programKodak gets $765M loan to make APIs under Defense Production Act.

British drugmaker GlaxoSmithKline and popular genetic testing company 23andMe have released human scientific trials for a collectively established cancer drug, according to Bloomberg.

Early-stage trials for a new cancer drug developed by the two companies are now underway. They developed the antibody drug to block CD96, a protein that triggers overactivity of another molecule in malignant growths.

Katie Adams –
Wednesday, July 29th, 2020
Print|Email.

” This is a new way of believing about drug advancement,” Hal Barron, MD, GlaxoSmithKlines primary clinical officer and president of research study and advancement, told Bloomberg. “And the principle is coming to bear.”.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.